The future of European drug development: An expert's view

Europe has a very strong heritage of developing drugs for a global market, with a wide range of both non-clinical and clinical skills. Additionally, when compared to the U.S. or Japan, Europe tends to be a rather cost-effective region for drug development activities. With a broad spectrum of cultural and educational backgrounds operating closely together, European drug development is much more globally minded than any other region of the world. This white paper by Fulcrum Pharma Developments Ltd. features an interview with Frank Fildes, former senior vice president and head of global development for AstraZeneca Worldwide.

There is, however, a number of current and future drug development issues that may affect the way the industry will operate in Europe. "There have been a lot of attempt to try to harmonize the regulatory process in Europe, and that has made some progress," says Dr. Fildes, who notes aspects of the trend to move key drug development activities from Europe to the U.S.

• Email This Page
• Print This Page